Trial Profile

Optimization of erlotinib for the treatment of patients with advanced non small cell lung cancer: an Italian randomized trial.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Docetaxel
Indications Non-small cell lung cancer
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms TAILOR

Most Recent Events

06 Jun 2017 Results (n=123) assessing predictive value of concurrent mutation of KRAS and LKB1 for resistance to erlotinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
24 Jul 2015 Results published in the Annals of Oncology.
02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com